Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01299961 · ClinicalTrials.gov registry record · Phase 3
Ultrasound Scores as Indication of Response to Subcutaneous Abatacept in Subjects With Rheumatoid Arthritis
A Phase 3 study, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 3
- Development phase
- 25
- Enrollment target
NCT01299961 is a Phase 3 study that has completed, run by University of California, Los Angeles. The registered enrollment target is 25 participants.
The verdict
NCT01299961, a Phase 3 study, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 25 participants
- Enrollment target
Study Summary
Rheumatoid arthritis (RA) is a chronic inflammatory disease (a long-lasting disease causing pain and swelling) associated with significant health problems. It is a difficult disease to manage as the disease is often unpredictable. RA causes inflammation (swelling) of the joints that can cause joint damage, deformity, and progressive disability and impairment. It is estimated that 1% of the world's population suffers from this disease. The purpose of this research study is to determine if a change in inflammation seen on the ultrasound is a good indicator of how subjects' rheumatoid arthritis is responding to treatment of subcutaneous abatacept at 3 weeks, 3 months, 6 months, and 12 months.
Interventions
- DRUG abatacept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2011-03 |
| Est. Completion | 2015-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01299961
The ClinicalTrials.gov registry entry for NCT01299961 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which abatacept is the first listed.
NCT01299961 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01299961 about?
NCT01299961 is a clinical study titled "Ultrasound Scores as Indication of Response to Subcutaneous Abatacept in Subjects With Rheumatoid Arthritis". Rheumatoid arthritis (RA) is a chronic inflammatory disease (a long-lasting disease causing pain and swelling) associated with significant health problems. It is a difficult disease to manage as the disease is often unpredictable. RA causes inflammation (swelling) of the joints that can cause joint ...
What is the current status of trial NCT01299961?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 25 participants. The study started on 2011-03. Estimated completion is 2015-02.
What interventions are being tested in trial NCT01299961?
The interventions under investigation include: abatacept (DRUG).
Who is sponsoring clinical trial NCT01299961?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.